Nanofármacos

LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: AU2024279964A1

The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).

CORTICOSTEROID NANOSUSPENSIONS AND USES THEREOF

Resumen de: AU2024265712A1

Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.

PROCESS FOR PREPARING DISPENSABLE TESTOSTERONE CREAM

Resumen de: AU2024276494A1

This invention relates to a process of preparing an oil-in-water emulsion comprising testosterone for use in a pump-action dispensing device. It further relates to the oil-in-water emulsion produced by the process of the invention, and the combination of the emulsion with a pump-action dispensing device.

Use of whey protein micelles for controlling postprandial glucose response

Resumen de: AU2025256158A1

A method for reducing postprandial glucose from a meal includes orally administering to an individual a composition containing whey protein micelles (WPM) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the WPM and within about one hour of the oral administration of the composition containing the WPM. For example, the meal can be administered about thirty minutes after the administration of the composition containing the WPM. The postprandial glucose is reduced relative to postprandial glucose from administering a corresponding composition comprising whey protein isolate. A method for reducing postprandial glucose from a meal includes orally administering to an individual a composition containing whey protein micelles (WPM) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the WPM and within about one hour of the oral administration of the composition containing the WPM. For example, the meal can be administered about thirty minutes after the administration of the composition containing the WPM. The postprandial glucose is reduced relative to postprandial glucose from administering a corresponding composition comprising whey protein isolate. ct c t

Ribose-modified cap analog and use thereof

Resumen de: AU2025201351A1

The present disclosure provides a ribose-modified cap analog and a use thereof, and belongs to the technical field of chemical and biological engineering. The ribose-modified cap analog has a structure of formula (I). The ribose-modified cap analog described herein can improve the stability of mRNA and/or the translation efficiency of mRNA. The present disclosure provides a ribose-modified cap analog and a use thereof, and belongs to the technical field of chemical and biological engineering. The ribose-modified cap analog has a structure of formula (I). The ribose-modified cap analog described herein can improve the stability of mRNA and/or the translation efficiency of mRNA. eb e b

Novel lipid nanoparticles for delivery of nucleic acids

Resumen de: AU2025256172A1

The invention relates to novel polymer conjugated lipids and to novel compositions comprising said novel polymer conjugated lipids useful for the delivery of nucleic acids into living cells. 5 The invention relates to novel polymer conjugated lipids and to novel compositions comprising said novel polymer 5 conjugated lipids useful for the delivery of nucleic acids into living cells. ct c t

METAL AQUO-COMPLEX MEDIATED SYNTHESIS OF ZINC OXIDE-BASED STRUCTURES

Resumen de: AU2024250977A1

Provided herein are dispersible powder compositions comprising metal oxide particles and water, as well as methods of preparing dispersible powder compositions.

IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION

Resumen de: WO2025052296A1

The present invention belongs to the field of biomedicine and drug delivery as well as pest and vector controls. The invention relates to a novel ionizable cationic lipid family incorporating silicon, which belongs to the trademark LipexSil® second generation lipids, wherein the tail is connected to the headgroup with biodegradable silyl acetal linker. Lipids containing silyl acetal linker(s) are state-of-the-art and are effective as ionizable cationic lipids in the formulation of empty or loaded lipid nanoparticles (LNPs). The novel linkers according to the invention are designed by means of proprietary borane catalysts WO2022129966. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, dsRNA, pDNA, micro RNA, circular DNA, small biologically active molecules) into the cells.

COMPOUND FOR DELIVERING DRUG, AND LIPOSOME AND DRUG CARRIER

Resumen de: EP4647421A1

The present invention provides a compound, which is a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof represented by formula (I):X1, X2, and X3 are each independently a C1-C15 alkyl group optionally substituted; R1 and R2 are each independently a C1-C40 alkyl group optionally substituted, a C1-C40 heteroalkyl group optionally substituted, a C2-C40 alkenyl group optionally substituted, a C2-C40 heteroalkenyl group optionally substituted, a C2-C40 alkynyl group optionally substituted, or a C2-C40 heteroalkynyl group optionally substituted; R3, R4, R5, and R6 are each independently H, halogen, or a C1-C3 alkyl group optionally substituted; the substituent group is independently selected from halogen, -OH, -SH, -NH2, -NO2, cyano, or C1-C3 alkyl. This compound has the advantages of low cytotoxicity, strong delivery capability, and good immunostimulatory effect.

INTERTUMORAL AND INTRATUMORAL DELIVERY OF CYTOKINES USING MESOPOROUS SILICA RODS AS AN IMMUNOMODULATING SYSTEM

Resumen de: WO2024148364A1

Embodiments of the invention include methods of treating conditions that are ameliorated by stimulating an immune response. In aspects, the methods include injection of mesoporous silica rods (MSRs) at or near an affected tissue. The MSRs can include a cytokine (e.g., IL-2 or IL-12) and/or an adjuvant. The MSRs can induce an innate immune response to treat cancer, infection and other ailments. The methods can include administering an additional medicament such as an immune checkpoint inhibitor.

一种黄芪多糖粉的制备工艺

Resumen de: CN120919078A

本申请涉及黄芪提取技术领域，尤其涉及一种黄芪多糖粉的制备工艺。该黄芪多糖粉的制备工艺包括将黄芪药材泡入浸泡液之中，加热提取出黄芪多糖和黄芪甲苷，分离出液相，浓缩所述液相得到浓缩液，加入生物包裹剂，喷雾干燥，得到黄芪多糖粉；所述浸泡液包括共晶溶剂和水；所述生物包裹剂能包裹黄芪多糖和黄芪甲苷。共晶溶剂通过非共价相互作用改变黄芪多糖和黄芪甲苷的晶体结构，提升黄芪多糖和黄芪甲苷的溶解性，该浸泡液加热提取相比于纯水加热提取能显著提升黄芪多糖和黄芪甲苷的提取率。生物包裹剂为可以被畜禽食用的物质。

一种磷脂包裹银/二氧化锰共沉淀颗粒MRI造影剂及其制备方法与应用

Resumen de: CN120919355A

本发明提供了一种磷脂包裹银/二氧化锰共沉淀颗粒MRI造影剂及其制备方法与应用。本发明制备的造影剂具有高效MRI造影性能，相比传统钆基造影剂，生物安全性更高，无重金属离子泄漏风险；同时具有精准靶向能力，磷脂层修饰的cRGD靶向分子可特异性识别肿瘤细胞表面高表达的整合素αvβ3，实现造影剂在肿瘤组织的富集，提高成像分辨率与病灶定位准确性。良好生物相容性和多功能诊疗一体化潜力，创新性地结合银/二氧化锰共沉淀内核与磷脂包裹结构，兼具良好的磁共振成像（MRI）造影性能与生物相容性，在肿瘤靶向成像、疾病诊断等医学影像领域展现出显著应用潜力，为MRI造影剂的发展提供了新方向。

用于递送药剂的脂质纳米颗粒

Resumen de: AU2024250986A1

The present disclosure provides compositions which enable the delivery of cargo, including therapeutic agents such as RNA, to organs or tissues in addition to the liver, lungs, and spleen, such as brain, heart, kidney, and muscle tissue. More specifically, the compositions comprise a plurality of lipid particles comprising an agent, cationic lipids and ionizable lipid.

一种基于可逆TTET机制的高效光控药物释放的纳米粒子及制备方法

Resumen de: CN120919309A

本发明公开一种基于可逆TTET机制的高效光控药物释放的纳米粒子及制备方法，属于光控药物释放技术领域；制备方法包括：向溶有4‑溴间二苯酚的甲基磺酸中加入4‑氯乙酰乙酸乙酯，并搅拌；后得到化合物1；将化合物1、带有羧基的药物分子、K2CO3和超干DMF混合，在氮气下加热反应，后得到前药Cou‑Drug；将2‑(2,4‑二氟苯基)‑吡啶和IrCl3·3H2O混合，在氮气下加入混合溶剂，加热回流反应，经冷却、抽滤、洗涤干燥后与吡啶‑2‑甲酸类衍生物、Na2CO3混合，在氮气下加入乙二醇乙醚，并加热反应；后经过蒸馏、萃取、干燥、提纯后得到光敏剂Ir complexes；将共嵌段聚合物、前药Cou‑Drug、光敏剂Ir complexes加入到THF中混合，得混合溶液；将混合溶液加入去离子水中搅拌，后经透析、过滤，得到纳米粒子水溶液。

一种基于组合免疫产生高效价抗血清的方法

Resumen de: CN120919301A

本发明公开了一种基于组合免疫产生高效价抗血清的方法，属于生物医药技术领域。本发明通过加入TLR激动剂和细胞因子作为免疫佐剂，其中，TLR激动剂激活固有免疫，为mRNA诱导的抗原特异性免疫反应提供良好的免疫微环境；细胞因子调节免疫细胞功能，促进免疫细胞对mRNA表达抗原的识别和应答。TLR激动剂和细胞因子通过协同作用，能够有效调节免疫细胞的功能，促进T细胞的增殖和分化，增强Th1型免疫反应，提高细胞免疫功能；同时促进B细胞产生高效价抗血清，增强体液免疫功能。与单纯mRNA免疫相比，采用本发明的组合免疫方法，能够得到效价显著提高的抗血清。

一种具有组织靶向和线粒体定位的纳米囊泡及其制备与应用

Resumen de: CN120919073A

本发明公开了一种具有组织靶向和线粒体定位的纳米囊泡及其制备与应用。所述纳米囊泡为为包载小分子线粒体膜稳定剂的髓核细胞膜，在髓核细胞的培养过程中添加四乙酰化N‑乙酰氨基甘露糖，使髓核细胞膜表面表达带有叠氮基团的唾液酸衍生物，从而通过生物正交反应在髓核细胞膜表面修饰三苯基膦阳离子。该纳米囊泡能够稳定线粒体膜结构，改善细胞衰老相关分泌表型释放以及线粒体功能，阻断mtDNA释放和SASP因子的产生，实现抗衰老、抗炎和组织退变干预，能够用于制备与线粒体膜损伤相关的组织退行性疾病的干预药物，或调控细胞衰老模型中的mtDNA泄漏和SASP释放的药物。具有广阔的应用前景和重要的临床转化价值。

一种含铂聚合物及其在制备成像或抗肿瘤产品方面的用途

Resumen de: CN120923794A

本发明涉及一种含铂聚合物及其在制备成像或抗肿瘤产品方面的用途，所述含铂聚合物由双羟基四价铂药、式I所示的光敏剂单体通过酸酐或二异氰酸酯进行缩合，然后由一端含有氨基或羟基的聚乙二醇封端得到。本发明通过轴向修饰Pt(Ⅳ)类药物的策略，将NIR‑II荧光单体BODTPE引入到聚合物链中，使含铂聚合物同时具有优良的肿瘤检测成像、靶向和杀伤作用。

一种红色抗菌纳米硒粒子及其制备方法

Resumen de: CN120919076A

本发明提供了一种红色抗菌纳米硒的制备方法，将羧甲基纤维素粉末与高碘酸盐溶液混合，进行羧甲基纤维素的氧化反应，获得氧化改性羧甲基纤维素粉末，再将氧化改性羧甲基纤维素粉末与多胺基聚合物溶液进行接枝反应，得到阳离子型胺基化改性羧甲基纤维素，然后将硒酸根物质溶解于去离子水中，待完全溶解后添加所得阳离子型胺基化改性羧甲基纤维素，加热搅拌，生成红砖色沉淀，最后离心干燥后得到所述纳米硒粒子。该方法解决了纳米硒粒子容易团聚的问题，制备的纳米硒粒子具有很高的生物活性和生物利用率，并且无额外还原剂使用。

一种用于癫痫治疗的超声响应仿生压电纳米药物及其制备方法和应用

Resumen de: CN120919312A

本发明涉及一种用于癫痫治疗的超声响应仿生压电纳米药物及其制备方法和应用，包括：经硫酸刻蚀后的铪基压电纳米颗粒UIO‑66‑NH2、抗癫痫药物、小胶质细胞膜、转铁蛋白受体靶向肽；其中，所述抗癫痫药物负载于经硫酸刻蚀后的铪基压电纳米颗粒中形成载药核心；所述小胶质细胞膜包覆于载药核心的外表面；所述转铁蛋白受体靶向肽连接于小胶质细胞膜上。本发明的超声响应仿生压电纳米药物入脑效率高，释药量稳定，制备方法路径清晰，适用于多种抗癫痫药物的靶向递送及癫痫等神经系统疾病的治疗与研究，其可采用静脉注射的给药方式，无创给药，能够避免手术带来的损伤，电刺激在体内产生，无需经过电极的植入与取出，避免了带来的二次损伤和感染。

一种治疗良性前列腺增生的siRNA制剂

Resumen de: CN120919153A

本发明公开了一种治疗良性前列腺增生的siRNA制剂，属于生物制药技术领域。通过分析人和大鼠SRD5A2的mRNA序列，设计出两种用于沉默SRD5A2蛋白表达的siRNA序列，并合成。两种siRNA经脂质体转染人正常前列腺基质永生化细胞，siRNA‑1和siRNA‑2均能达到较好的SRD5A2基因沉默效果。对丙酸睾酮诱导的良性前列腺增生模型大鼠静脉注射两种siRNA‑脂质体复合物，siRNA‑1和siRNA‑2在大鼠体内均能有效沉默SRD5A2表达。前列腺增生模型大鼠经两种siRNA治疗后，血清中二氢睾酮DHT含量比未治疗的模型组显著降低，前列腺指数也显著减小。

表皮葡萄球菌囊泡和姜黄衍生外泌体样囊泡的融合膜及其制备方法和应用

Resumen de: CN120919253A

本发明公开了一种表皮葡萄球菌囊泡和姜黄衍生外泌体样囊泡的融合膜及其制备方法和应用。本发明将表皮葡萄球菌囊泡和姜黄衍生外泌体样囊泡融合，得到HMVs，通过体外实验验证其抗菌效果，然后装载于透明质酸微针中，该HMVs MNs纳米体系可通过按压于痤疮皮损处局部给药，Balb/c小鼠体内实验证明其具有较显著的抗菌、抗炎的疗效。因此HMVs MNs具有较好的治疗痤疮的应用潜能。

一种鹿茸干细胞条件培养基仿生纳米颗粒制剂的制备方法及其应用

Resumen de: CN120919072A

本发明公开了一种鹿茸干细胞条件培养基仿生纳米颗粒制剂的制备方法，包括以下步骤：S1、鹿茸干细胞的分离培养，并制得P3细胞，采用P3细胞制备鹿茸干细胞条件培养基ABPCs‑CM以备用；S2、采用S1所得鹿茸干细胞条件培养基ABPCs‑CM合成鹿茸干细胞条件培养基纳米颗粒CM‑NPS；S3、制备中性粒细胞膜；S4、将S2所得的鹿茸干细胞条件培养基纳米颗粒CM‑NPS与S3所得的中性粒细胞膜合成鹿茸干细胞条件培养基仿生纳米颗粒制剂，本发明中性粒细胞膜仿生结构，显著提高炎症部位靶向效率。

一种蛋黄-蛋壳结构Bi2S3@C/Fe3O4纳米颗粒及其制备方法和应用

Resumen de: CN120919074A

本发明公开了一种蛋黄‑蛋壳结构Bi2S3@C/Fe3O4纳米颗粒及其制备方法和应用，涉及纳米材料技术领域，所述纳米颗粒包括碳壳层和核心层，碳壳层和核心层之间通过中空层连接，所述碳壳层的材料为酚醛树脂碳，所述碳壳层中均匀分布超顺磁性Fe3O4纳米颗粒，所述核心层的材料为Bi2S3纳米颗粒，所述核心层的直径为40～60nm，所述碳壳层的厚度为5～25nm；本发明的纳米颗粒在有效浓度下能够到达肿瘤部位并实现最佳治疗效果，且能在外部磁场引导下优先聚集于颅内肿瘤处。本发明的纳米颗粒材料合成工艺易于实现、生物安全性高，3D打印磁性头盔的应用可扩展至人体其他部位，为胶质瘤的精准治疗提供可产业化的解决方案。

一种稀土复合纳米材料及其制备方法和应用

Resumen de: CN120919314A

本发明属于有机‑无机杂化纳米材料制备技术领域，具体涉及一种稀土复合纳米材料及其制备方法和应用。通过配体交换在Na基稀土纳米颗粒表面同时修饰两种光敏剂二氢卟吩e6与孟加拉玫瑰红，实现高效的光动力学治疗效果。本发明合成了核‑壳‑壳结构Na基稀土纳米颗粒，在1550 nm激光激发下具有较强的红、绿光发射。1550 nm激光在生物组织中的光散射极小，能够提高激光的穿透深度和聚焦能力，有望实现深度组织的光动力学治疗。在纳米粒子表面通过配体交换反应直接修饰光敏剂二氢卟吩e6与孟加拉玫瑰红，相对于两亲性表面活性剂包裹或通过二氧化硅负载的方法，能够显著提高稀土离子与光敏剂之间的能量传递效率，提高光动力效果。

一种同时抑制成纤维细胞激活和血管新生的纳米药物

Nº publicación: CN120919075A 11/11/2025

Solicitante:

郑州大学第一附属医院

Resumen de: CN120919075A

本申请属于肿瘤防治技术领域，具体涉及一种能够同时抑制成纤维细胞激活和血管新生的纳米药物。所述同时抑制成纤维细胞激活和血管新生的纳米药物为负载修饰改造后的松弛素类似物多肽B7‑33的仿生纳米载体SNPs。本申请所采用的双功能仿生纳米药物B7‑33‑SNPs，能够靶向递送至肿瘤组织，同时抑制成纤维细胞激活介导的细胞外基质以及血管新生，同时也抑制了成纤维细胞激活介导的血管新生。这些结果可为胆管癌的针对性防治奠定良好的技术基础，同时也为其他疾病的防治提供了新的技术思路。